Absolutely right Lowed
That's really the rationale behind the 'allcomer' PD-1 status TACTI trials.
Not withstanding dozens of other combo trials with Keytruda.
So what would force their hand to bid/ license efti?
Another suitor? More mature TACTI data? IP cliff coming for Keytruda?
Must add - thought NSCLC - latest ORR % was disappointing (but explained by data combination and different cohort types - age and pre treatments).
Absolutely right LowedThat's really the rationale behind...
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.100(23.0%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 40.0¢ | 23.0¢ | $16.23M | 50.19M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 704297 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 102135 | 2 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |